☰

Holly A. Stessman, Ph.D. - Publications

Affiliations: 
2013 Molecular, Cellular, Developmental Biology and Genetics University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Molecular Biology, Cell Biology, General Biology
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Duncan RM, Reyes L, Moats K, Robinson RM, Stessman HA, Dolloff NG. Abstract 3840: ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy Cancer Research. 79: 3840-3840. DOI: 10.1158/1538-7445.Am2019-3840  0.392
2016 Wang T, Guo H, Xiong B, Stessman HA, Wu H, Coe BP, Turner TN, Liu Y, Zhao W, Hoekzema K, Vives L, Xia L, Tang M, Ou J, Chen B, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nature Communications. 7: 13316. PMID 27824329 DOI: 10.1038/ncomms13316  0.348
2016 Mitra AK, Stessman HA, Schaefer RJ, Wang W, Myers CL, Van Ness BG, Beiraghi S. Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate. Frontiers in Genetics. 7: 88. PMID 27242896 DOI: 10.3389/fgene.2016.00088  0.522
2015 Turner TN, Hormozdiari F, Duyzend MH, McClymont SA, Hook PW, Iossifov I, Raja A, Baker C, Hoekzema K, Stessman HA, Zody MC, Nelson BJ, Huddleston J, Sandstrom R, Smith JD, et al. Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA. American Journal of Human Genetics. PMID 26749308 DOI: 10.1016/J.Ajhg.2015.11.023  0.336
2015 Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, Kumar S, Rajkumar V, Van Ness B. Single-cell analysis of targeted transcriptome (SCATTome) predicts drug sensitivity of single cells within human myeloma tumors. Leukemia. PMID 26710886 DOI: 10.1038/Leu.2015.361  0.459
2015 Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, Raja A, Coe BP, Stessman HA, He ZX, Leal SM, Bernier R, Eichler EE. Excess of rare, inherited truncating mutations in autism. Nature Genetics. 47: 582-8. PMID 25961944 DOI: 10.1038/Ng.3303  0.344
2015 Mitra AK, Mukherjee U, Harding T, Stessman H, Li Y, Jin J, Kumar SK, Rajkumar SV, Ness BGV. Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors Blood. 126: 4249-4249. DOI: 10.1182/Blood.V126.23.4249.4249  0.503
2014 O'Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, Vives L, Baker C, Hiatt JB, Nickerson DA, Bernier R, Shendure J, Eichler EE. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nature Communications. 5: 5595. PMID 25418537 DOI: 10.1038/Ncomms6595  0.334
2014 Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. Journal of Cancer. 5: 720-7. PMID 25368671 DOI: 10.7150/Jca.9864  0.681
2014 Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, Smith JD, Paeper B, Nickerson DA, Dea J, Dong S, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 515: 216-21. PMID 25363768 DOI: 10.1038/Nature13908  0.341
2014 Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 28: 2263-7. PMID 25005244 DOI: 10.1038/leu.2014.214  0.621
2014 Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, Witherspoon K, Gerdts J, Baker C, Vulto-van Silfhout AT, Schuurs-Hoeijmakers JH, Fichera M, Bosco P, Buono S, Alberti A, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell. 158: 263-76. PMID 24998929 DOI: 10.1016/J.Cell.2014.06.017  0.336
2014 Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 156: 872-7. PMID 24581488 DOI: 10.1016/J.Cell.2014.02.002  0.356
2014 Stessman HA, Mansoor A, Linden MA, Van Ness B, Baughn LB. Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia & Lymphoma. 55: 220-2. PMID 23734619 DOI: 10.3109/10428194.2013.797575  0.611
2014 Mitra AK, Stessman H, Linden MA, Van Ness B. Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines Blood. 124: 3385-3385. DOI: 10.1182/Blood.V124.21.3385.3385  0.608
2013 Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. Plos One. 8: e77608. PMID 24204892 DOI: 10.1371/Journal.Pone.0077608  0.685
2013 Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 27: 2075-7. PMID 23728080 DOI: 10.1038/Leu.2013.148  0.585
2013 Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics. 12: 1140-50. PMID 23536725 DOI: 10.1158/1535-7163.Mct-12-1151  0.693
2013 Lulla A, Stessman H, Dicker D, Ness BV, El-Deiry W, Dolloff NG. Abstract 1020: VRC2, a novel bortezomib re-sensitizing compound for the treatment of multiple myeloma. Cancer Research. 73: 1020-1020. DOI: 10.1158/1538-7445.Am2013-1020  0.493
2011 Baughn LB, Stessman H, Mansoor A, Van Ness B. Modeling Proteasome Inhibition in Lymphoma Blood. 118: 4946-4946. DOI: 10.1182/Blood.V118.21.4946.4946  0.532
2011 Stessman H, Baughn LB, Sarver AG, Mansoor A, Wu TG, Janz S, Ness BV. Good and Poor Response Gene Expression Signatures to Proteasome Inhibitors Using a Mouse Model of Multiple Myeloma Blood. 118: 1843-1843. DOI: 10.1182/Blood.V118.21.1843.1843  0.516
2011 Stessman H, Baughn LB, Mansoor A, Van Ness B. Expression of Germinal Center B Cell Markers in Bortezomib-Resistant Multiple Myeloma Cells Blood. 118: 129-129. DOI: 10.1182/Blood.V118.21.129.129  0.522
Show low-probability matches.